Steris Acquires Synergy for $1.9 Billion
Steris acquires Synergy Health, a UK-based outsourcing company focused on sterilization, for &1.9 billion USD.
Steris offered to acquire Synergy Health for $1.9 billion in cash and stocks. Steris, a company specializing in infection prevention, contamination control, surgical, and critical care technology, will benefit from the UK-based Synergy Health, specializing in outsourced sterilization services. In fiscal 2014, Synergy generated approximately $604 million in revenue and approximately $161 million in adjusted earnings before EBITDA.
Upon closing, expected in March 2015 according to a press release, the combined business will have approximately $2.6 billion in annual revenue. The acquisition will save the new company approximately $30 million annually in pre-tax cost savings due to a lowered tax rate. Similar to many mergers and acquisitions in the past year that have been dependent upon tax inversion, Steris will see a lowered tax rate of 25%, as opposed to the US corporate income tax rate of 35%, when combined with the UK company.
Source: Steris
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
